Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Mutation causing light chain amyloidosis identified

Mutation causing light chain amyloidosis identified

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Agent Orange exposure: VA adds three new illnesses to list of health problems

Agent Orange exposure: VA adds three new illnesses to list of health problems

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Symptomless blood disorder MGUS not a precursor of serious diseases

Symptomless blood disorder MGUS not a precursor of serious diseases

New small molecule approach to Alzheimer's disease treatment

New small molecule approach to Alzheimer's disease treatment